Wei Gao

Dr. Wei Gao


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2020 in Discover Nano
Verified
Journal Article
Open access
PDF file
CLChunyong Liang
Chunyong Liang
JSJiying Song
Jiying Song
YZYongguang Zhang
Yongguang Zhang
YGYaping Guo
Yaping Guo
MDMeigui Deng
Meigui Deng
JZJimin Zhang
Jimin Zhang
Near-infrared (NIR)-light responsive graphene have been shown exciting effect on cancer photothermal ablation therapy. Herein, we report on the preparation of Fe3O4-decorated hollow graphene microspheres (rGO@Fe3O4) by a facile spray drying and coprecipitation method for the magnetically targeted and NIR-responsive chemo-photothermal combination therapy. The microspheres displayed very high specific surface area (~ 120.7 m2 g−1) and large pore volume (~ 1.012 cm3 g−1), demonstrating distinct advantages for a high loading capacity of DOX (~ 18.43%). NIR triggered photothermal effect of the rGO@Fe3O4microspheres responded in an on-off manner and induced a high photothermal conversion efficiency. Moreover, The Fe3O4on the microspheres exhibited an excellent tumor cells targeting ability. The chemo-photothermal treatment based on rGO@Fe3O4/DOX showed superior cytotoxicity towards Hela cells in vitro. Our studies indicated that rGO@Fe3O4/DOX microcapsules have great potential in combined chemo-photothermal cancer treatment.

28 June 2022 in Materials
Verified
Journal Article
Open access
PDF file
XFXin Feng
Xin Feng
MLMingjun Li
Mingjun Li
JWJianming Wang
Jianming Wang
XZXianrui Zou
Xianrui Zou
HWHongshui Wang
Hongshui Wang
CLChunyong Liang
Chunyong Liang
It is critical to construct stimuli-responsive multifunctional nanoparticles for the drug delivery system for cancer treatment. Zeolitic imidazolate framework-8 (ZIF-8) has a large specific surface area and decomposes quickly under acidic conditions, which presents an excellent potential in pH-sensitive drug carriers. However, the mere chemotherapeutic drug loaded into ZIF-8 is a monotherapy and may restrict the therapeutic efficacy of malignancies. In this work, an effective nanoparticle-based delivery platform is established to simultaneously encapsulate doxorubicin (DOX) and MXene quantum dot (MQD) in ZIF-8 nanoparticles (MQD@ZIF-8/DOX). Under near-infrared (NIR) laser (808 nm) and UV light (365 nm) irradiation, MQD@ZIF-8 demonstrates a high photothermal conversion efficiency and reactive oxygen species (ROS) production, which shows excellent photothermal therapy and photodynamic therapy effects. Furthermore, the release of DOX-loaded into MQD@ZIF-8 nanoparticles is significantly increased under NIR laser irradiation and at pH 5.6, indicating that acidic conditions and NIR laser irradiation can be effectively combined to stimulate the drug release. The cellular experiments show that MQD@ZIF-8/DOX has an obvious killing effect on HeLa cells and achieves the combined anti-tumor effect of chemotherapy and phototherapy.

4 December 2019 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
YDYingqi Dai
Yingqi Dai
SZsong zhonghua
song zhonghua
JZJinqing Zhang
Jinqing Zhang
WGWei Gao
Wei Gao
Objectives In this study, we examined available articles from on-line databases to comprehensively investigate the effect of the XPC (xeroderma pigmentosum complementation group C) rs2228000 polymorphism on the risk of different types of clinical cancer. Method We conducted a group of overall and subgroup pooling analyses after retrieving the data from four databases (updated to September 2019). The P value of association, OR (odds ratios) and 95% CI (confidence interval) were calculated. Results We selected a total of 71 eligible studies with 26,835 cancer cases and 37,069 controls from the 1,186 retrieved articles. There is an enhanced susceptibility to bladder cancer cases under T vs. C [P=0.004; OR (95% CI) =1.25 (1.07, 1.45)], TT vs. CC [P=0.001; 1.68 (1.25, 2.26)], CT+TT vs. CC [P=0.016; 1.26 (1.04, 1.53)], and TT vs. CC+ CT [P=0.001; 1.49 (1.18, 1.90)] compared with negative controls. Additionally, there is an increased risk of breast cancer under T vs. C, TT vs. CC and TT vs. CC+ CT (P1). Nevertheless, there is a decreased risk of gastric cancer cases in China under T vs. C [P=0.020; 0.92 (0.85, 0.99)], CT vs. CC [P=0.001, 0.83 (0.73, 0.93)], and CT+TT vs. CC [P=0.003, 0.84 (0.76, 0.94)]. Conclusions The TT genotype of XPC rs2228000 may be linked to an increased risk of bladder and breast cancer, whereas the CT genotype is likely to be associated with reduced susceptibility to gastric cancer in the Chinese population.

20 August 2018 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
ZSZhen Sun
Zhen Sun
WGWei Gao
Wei Gao
JCJiang-Tao Cui
Jiang-Tao Cui
There are different and inconsistent conclusions regarding the genetic relationship between the human tumor suppressor p53 (TP53) rs1042522 polymorphism and the risk of oral squamous cell carcinoma (OSCC) and oral leukoplakia (OL). Therefore, the aim of the study was to comprehensively reassess this association through the performance of an updated meta-analysis. After searching the available databases, we systematically screened and included the eligible case-control studies, which contain the full genotype frequency data of the TP53 rs1042522 polymorphism for both OSCC/OL patients and the negative control groups. PA (P-value of the association test) and ORs (odd ratios) with their corresponding 95% CIs (confidence intervals) were calculated to quantitatively evaluate the influence of TP53 rs1042522 on the susceptibility of patients to OSCC or OL. In total, twenty eligible case-control articles were finally enrolled. Compared with the controls, no increased or decreased risk of OSCC was observed in the cases for six genetic models including allele C vs. G (PA = 0.741), carrier C vs. G (PA = 0.853), homozygote CC vs. GG (PA = 0.085), heterozygote GC vs. GG (PA = 0.882), dominant GC + CC vs. GG (PA = 0.969), and recessive CC vs. GG + GC (PA = 0.980). Furthermore, no statistically significant difference between the cases and controls was detected in most subgroup meta-analyses (PA > 0.05). For the risk of OL, we did not observe the difference between the cases and controls for most genetic models in the overall meta-analysis and subsequent subgroup analysis (PA > 0.05). Begg’s test and Egger’s test excluded the large risk of publication bias within the included studies in the meta-analysis of OSCC. The sensitivity analysis indicated the above relatively stable results. Our updated meta-analysis (based on the current evidence) shows that TP53 rs1042522 may not confer susceptibility to OSCC. In addition, for the first time, we provided evidence regarding the negative association between TP53 rs1042522 and OL risk.

5 June 2023 in Discover Oncology
Verified
Journal Article
Open access
PDF file
WZWeihao Zhang
Weihao Zhang
YXYongjie Xie
Yongjie Xie
XYXin Yu
Xin Yu
CLChangfu Liu
Changfu Liu
WGWei Gao
Wei Gao
TSTongguo Si
Tongguo Si
Background PDAC is a highly malignant and immune-suppressive tumor, posing great challenges to therapy. Methods In this study, we utilized multi-center RNA sequencing and non-negative matrix factorization clustering (NMF) to identify a group of metabolism-related genes that could effectively predict the immune status and survival (both disease-free survival and overall survival) of pancreatic ductal adenocarcinoma (PDAC) patients. Subsequently, through the integration of single cell sequencing and our center's prospective and retrospective cohort studies, we identified ABHD17C, which possesses metabolic and immune-related characteristics, as a potential biomarker for predicting the prognosis and response to anti-PD1 therapy in PDAC. We then demonstrated how ABHD17C participates in the regulation of the immune microenvironment through in vitro glycolytic function experiments and in vivo animal experiments. Results Through screening for pancreatic cancer metabolic markers and immune status, we identified a critical molecule that inhibits pancreatic cancer survival and prognosis. Further flow cytometry analysis confirmed that ABHD17C is involved in the inhibition of the formation of the immune environment in PDAC. Our research found that ABHD17C participates in the metabolic process of tumor cells in in vitro and in vivo experiments, reshaping the immunosuppressive microenvironment by downregulating the pH value. Furthermore, through LDHA inhibition experiments, we demonstrated that ABHD17C significantly enhances glycolysis and inhibits the formation of the immune suppressive environment. In in vivo experiments, we also validated that ABHD17C overexpression significantly mediates resistance to anti-PD1 therapy and promotes the progression of pancreatic cancer. Conclusion Therefore, ABHD17C may be a novel and effective biomarker for predicting the metabolic status and immune condition of PDAC patients, and provide a potential predictive strategy for anti-PD1 therapy in PDAC.